Progesterone deficiency

What it is

Progesterone deficiency is a hormonal state in which progesterone levels are inadequate for the body's needs at a given point in the menstrual cycle or pregnancy, affecting an estimated 5–10% of women of reproductive age and a substantially higher proportion during perimenopause. Also called low progesterone or luteal phase defect (LPD) when it specifically involves insufficient post-ovulatory progesterone, the condition is not always a discrete ICD-coded diagnosis — but it describes a clinically meaningful pattern with measurable consequences for cycle regularity, fertility, and mood.

Progesterone is produced primarily by the corpus luteum after ovulation and, from around 10 weeks of gestation onward, by the placenta. It prepares the uterine lining for embryo implantation, counterbalances estrogen's proliferative effects on the endometrium, supports thyroid function, and modulates mood through its neurosteroid metabolites. When production falls short, the downstream effects range from spotting and heavy periods to recurrent early pregnancy loss.

In Canada, a mid-luteal serum progesterone test — available through LifeLabs, Dynacare, or hospital labs — is the standard first step in evaluation. A result below 16–30 nmol/L (5–10 ng/mL), drawn approximately 7 days before the expected next period, suggests inadequate luteal function.

Causes and mechanism

Progesterone deficiency arises when ovulation either does not occur or produces a corpus luteum of insufficient quality. The main pathways:

Cause	Mechanism	Common context
Anovulation (e.g., PCOS)	No corpus luteum forms; no progesterone produced	Most common cause of anovulatory cycles in reproductive-age women
Luteal phase defect	Corpus luteum forms but produces too little progesterone; luteal phase < 10 days	Unexplained infertility, recurrent miscarriage
Perimenopause	Rising frequency of anovulatory cycles as ovarian reserve declines	Women in their 40s
Hyperprolactinaemia	Elevated prolactin suppresses the LH surge needed for ovulation	Pituitary adenoma, certain medications
Thyroid dysfunction	Both hypothyroidism and hyperthyroidism impair progesterone production and clearance	Often co-presents with cycle irregularity
Chronic stress	Cortisol and progesterone share the precursor pregnenolone; sustained stress diverts it toward cortisol	HPA-axis dysregulation
Excessive exercise / low body weight	Suppresses GnRH pulsatility, reducing LH and FSH and impairing ovulation quality	Athletes, restrictive eating

In early pregnancy, insufficient progesterone before the luteo-placental shift at approximately 10 weeks can contribute to first-trimester loss. Whether low progesterone is a cause or a consequence of a failing pregnancy is an important clinical distinction (see Limitations section).

Symptoms and diagnosis

Symptoms reflect progesterone's roles in cycle regulation, endometrial balance, and neurosteroid activity.

Menstrual and reproductive symptoms

• Irregular, short, or absent cycles
• Luteal phase shorter than 10 days (between ovulation and period onset)
• Heavy menstrual bleeding from unopposed estrogen stimulation of the endometrium
• Premenstrual spotting
• Difficulty conceiving or recurrent early miscarriage

Premenstrual symptoms

• Worsened PMS or PMDD-like symptoms concentrated in the second half of the cycle
• Breast tenderness, bloating, fluid retention
• Mood changes, anxiety, irritability

General symptoms

• Fatigue, low mood, and sleep disturbances — though these overlap with many other conditions

Diagnostic workup

1. Mid-luteal serum progesterone: drawn ~7 days before the expected next period (day 21 of a 28-day cycle). A level below 16–30 nmol/L suggests inadequate luteal function.
2. Hormone panel: FSH, LH, estradiol, prolactin, TSH, and androgens to identify contributing causes.
3. Basal body temperature charting: a short or absent post-ovulatory temperature rise supports a luteal phase defect.
4. Pelvic ultrasound: assesses ovulation and endometrial thickness.
5. Serial progesterone in early pregnancy: considered in women with recurrent miscarriage.

Treatment options

Treatment depends on the underlying cause and the clinical goal — cycle regulation, fertility support, or symptom management.

Addressing root causes first Treating PCOS, thyroid dysfunction, or hyperprolactinaemia often restores ovulatory function. Reducing excessive exercise, restoring a healthy body weight, and managing chronic stress can meaningfully improve luteal phase quality without pharmacological intervention.

Progesterone supplementation

• Oral micronized progesterone (Prometrium, available in Canada; Utrogestan in some markets): taken in the luteal phase to supplement endogenous production, or in early pregnancy for recurrent miscarriage support. The 2019 PRISM trial (Coomarasamy et al., NEJM) found a modest but meaningful improvement in live birth rates with vaginal progesterone in women with unexplained recurrent miscarriage and first-trimester bleeding.
• Vaginal progesterone (Crinone gel, Cyclogest): standard luteal phase support in IVF cycles; also used in early pregnancy.
• Topical progesterone cream: available over the counter in some formulations, but bioavailability is lower and less predictable than oral or vaginal routes. Not recommended as a substitute for prescribed progesterone in fertility or endometrial-protection contexts.

For fertility Letrozole or clomiphene can improve ovulation quality in women with anovulatory cycles. hCG injections support the corpus luteum by mimicking LH. Progesterone supplementation after IVF is standard of care.

For cycle regulation and endometrial protection Cyclical progestogen therapy protects the endometrium from unopposed estrogen and regulates bleeding in women not seeking pregnancy. In Canada, Prometrium is the most commonly prescribed oral micronized progesterone and is listed on several provincial formularies, though coverage varies by province and indication.

Canadian patients seeking assessment can access hormone testing and prescriptions through their family physician, a gynaecologist, or virtual care platforms such as Felix, Maple, Cleo, Phoenix, or others — comparing services on cost, wait times, and scope before choosing.

When to see a clinician in Canada

Book an appointment if you are experiencing:

• Consistently short cycles or a second half of the cycle shorter than 10 days
• Spotting that begins several days before your period
• Heavy periods alongside other hormonal symptoms
• Difficulty conceiving after 12 months of trying (or 6 months if you are over 35)
• Two or more first-trimester miscarriages
• Severe premenstrual symptoms concentrated in the luteal phase

A mid-luteal progesterone blood test — requisitioned by a family physician and processed at LifeLabs or Dynacare — is a straightforward starting point. Timing the draw correctly (7 days before the expected next period, not a fixed cycle day) is important for an accurate result.

Limitations and open questions

Research is still emerging on several key questions. The diagnostic threshold for luteal phase defect is not universally agreed upon: some guidelines use a single mid-luteal progesterone below 16 nmol/L, others require multiple low readings or a luteal phase shorter than 10 days, and no single test is considered definitive. The clinical entity of "luteal phase defect" itself remains contested in reproductive medicine, with some authorities questioning whether it is a discrete condition or a spectrum of normal variation.

The causal relationship between low progesterone and miscarriage is also unsettled. In many first-trimester losses, low progesterone reflects a pregnancy that is already failing rather than being the primary driver of loss — which limits the predictive and therapeutic value of a single early-pregnancy progesterone measurement. The PRISM trial showed benefit for progesterone supplementation in women with recurrent miscarriage and first-trimester bleeding, but the evidence is less clear for women without a prior miscarriage history.

Health Canada has not issued specific guidance on progesterone supplementation for luteal phase defect outside of assisted reproduction contexts. The role of topical progesterone cream for cycle symptoms remains poorly characterized in randomized trials. Clinicians and patients should weigh these uncertainties when interpreting test results and considering treatment.